PROCEPT BioRobotics (NASDAQ:PRCT) Hits New 1-Year Low Following Weak Earnings

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) hit a new 52-week low during mid-day trading on Thursday following a weaker than expected earnings announcement. The stock traded as low as $19.35 and last traded at $20.9420, with a volume of 1508954 shares changing hands. The stock had previously closed at $27.84.

The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The business had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.35) EPS.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Company outlined a multi‑year plan and issued 2026 guidance of $390M–$410M, signaling a path to higher revenue as it pursues pricing discipline and commercial realignment; the investor day attempted to frame a roadmap to sustainable growth. PROCEPT outlines $390M–$410M revenue target for 2026
• Positive Sentiment: Certain sell‑side firms maintained constructive ratings (buy/overweight/outperform) even after trimming targets, which leaves upside scenarios if execution and revenue recovery accelerate. Analyst updates (summary)
• Neutral Sentiment: Q4 results showed revenue grew ~11.9% YoY and gross profit improved, and operating and net losses narrowed versus a year ago — a mixed quarter that demonstrates progress but also falling short of market expectations. Q4 earnings highlights
• Neutral Sentiment: Investor‑day materials and the earnings call transcript provide detail on assumptions behind guidance and the commercial reset; these are useful for modeling recovery timing but don’t eliminate execution risk. Investor Day slideshow
• Negative Sentiment: EPS and revenue missed consensus (EPS -$0.53 vs. -$0.32 estimate; revenue below forecasts), which triggered immediate downward pressure as investors re‑priced near‑term growth expectations. Q4 miss coverage
• Negative Sentiment: Several analysts cut price targets and/or downgraded the stock (examples: Jefferies to Hold; BofA to Underperform with $20 PT; Leerink, TD Cowen and Piper lowered targets), increasing short‑term downside risk and contributing to weaker sentiment. Analyst downgrades and price target changes
• Negative Sentiment: A securities‑fraud investigation by Ademi LLP into PROCEPT’s disclosures emerged, adding legal and headline risk that can prolong volatility and deter risk‑tolerant buyers. Ademi LLP investigation notice
• Negative Sentiment: Shares reached a new 52‑week low and traded at elevated volumes around these announcements, reflecting broad selling pressure and a reassessment of near‑term execution and guidance credibility. 52-week low coverage

Analysts Set New Price Targets

PRCT has been the topic of several analyst reports. Jefferies Financial Group downgraded PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research report on Thursday. TD Cowen dropped their price objective on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating for the company in a research note on Thursday. UBS Group assumed coverage on shares of PROCEPT BioRobotics in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Bank of America cut shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $38.00 to $20.00 in a research note on Thursday. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Hold” and an average price target of $41.90.

Institutional Trading of PROCEPT BioRobotics

Institutional investors and hedge funds have recently made changes to their positions in the business. Alliancebernstein L.P. lifted its holdings in PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after acquiring an additional 1,218,815 shares during the period. Westfield Capital Management Co. LP increased its position in shares of PROCEPT BioRobotics by 23.3% during the third quarter. Westfield Capital Management Co. LP now owns 1,970,147 shares of the company’s stock worth $70,315,000 after acquiring an additional 371,798 shares during the period. Mackenzie Financial Corp raised its stake in shares of PROCEPT BioRobotics by 8.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after acquiring an additional 118,971 shares in the last quarter. Finally, Chicago Capital LLC boosted its holdings in shares of PROCEPT BioRobotics by 175.7% in the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after purchasing an additional 999,873 shares during the period. 89.46% of the stock is currently owned by institutional investors.

PROCEPT BioRobotics Stock Performance

The firm has a 50 day moving average of $30.00 and a 200-day moving average of $33.53. The company has a market cap of $1.27 billion, a P/E ratio of -13.27 and a beta of 0.99. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.